D-Glutamine
- Generic Name
- D-Glutamine
- Brand Names
- Endari
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O3
- CAS Number
- 5959-95-5
- Unique Ingredient Identifier
- 63HB36CA2Y
- Background
A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells.
- Indication
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older .
- Associated Conditions
- Osteoporosis, Acute Complications of Sickle Cell Disease
- Associated Therapies
- -
Effects of Oral Care With Glutamine on Oral Health, Oral Flora and Incidence of Pneumonia After Neurosurgery With Microbiome Analysis
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Yanzhao
- Target Recruit Count
- 100
- Registration Number
- NCT03867214
- Locations
- 🇨🇳
Xijing Hospital, Xi'an, China
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02961816
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
- First Posted Date
- 2016-03-08
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02701673
Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02589145
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2014-07-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02114502
Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 14
- Registration Number
- NCT02012608
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 61
- Registration Number
- NCT01983969
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT01952847
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2014-05-28
- Lead Sponsor
- Yuejiang Liu
- Target Recruit Count
- 33
- Registration Number
- NCT01794884
- Locations
- 🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib
- Conditions
- Interventions
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Beth Faiman
- Target Recruit Count
- 9
- Registration Number
- NCT01783522
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.